Latest News and Press Releases

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the...

Delray Beach, FL, March 27, 2026 (GLOBE NEWSWIRE) -- The global surgical instrument tracking systems market is set to nearly double, growing from USD 0.37 billion in 2025 to USD 0.75 billion by...

South San Francisco, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- The California Institute for Regenerative Medicine (CIRM) celebrates a major milestone in the agency's 21-year history: the first...

DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next...

LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Disc Medicine, Inc. (“Disc Medicine" or the "Company") (NASDAQ: IRON) investors that the firm has initiated an...

Independent oversight reinforces manufacturing, supply chain integrity, and federal readiness for a platform designed to scale across multiple indications SPRING BRANCH, Texas, March 27, 2026 ...

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 0/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development...

RUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and...

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer...

Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range...

La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple ...

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...

Arletta Pharma reports >60% clitoral blood flow improvement with Lybrido™ in Phase II study, achieving statistical significance in women with FSIAD.

sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline...

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and...

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a...

Autolus announces its operational and financial results for the fourth quarter and full year ended December 31, 2025.

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for a...

Pruritus therapeutics market to reach $15.58 Bn by 2035, driven by rising skin disorders, strong biologics pipeline, and expanding global treatment demand.

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- A Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) anunciou hoje que deu entrada em um Pedido de Autorização de Comercialização (MAA) à Agência Nacional...

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to...

Gelatine Sculpt gelatin trick recipe claims, bariatric jelly terminology, GLP-1 marketing references, ingredient disclosure, and label verification.

MEDVi tirzepatide GLP-1 pricing, compounded medication access, telehealth structure, and 2026 regulatory context based on publicly available info

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between...

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

RA'ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and...

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under...

SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy...

GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum -- Life Sciences: R2 Secures 600‑System Commitment in China -- Spectrum: Recent network launches set to...

Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital...

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s...

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health...

On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase...

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment...

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to...

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30...

Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext...

LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action...

New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.

New class action for Inovio (INO) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/7/2026.

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.

Outgrow the chemical era. HairSmart leads 2026’s "Clean Bio-Hacking" trend, fusing FDA-cleared LLLT with Ayurveda for side-effect-free hair restoration.

Fairfield, Connecticut, March 26, 2026 (GLOBE NEWSWIRE) -- Bigelow Tea, America's number one family and woman-owned tea company, sources only premium ingredients from the United States and from...